[MicroRNA Analysis for Extramedullary Multiple Myeloma Relapse].

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Multiple myeloma (MM) is a common blood cancer where patient survival is impacted by extramedullary relapse (EM).
• The mechanisms driving EM in MM are not well understood.
• MicroRNAs (miRNAs) are key regulators of cellular processes and have been implicated in MM pathogenesis.

Purpose of the Study:

• To investigate the role of miRNAs in the development of extramedullary relapse (EM) in multiple myeloma (MM).
• To identify differentially expressed miRNAs between MM patients and EM patients.

Main Methods:

• Next-generation sequencing was used to analyze miRNA expression in bone marrow samples.
• Samples included 39 from MM patients at diagnosis and 9 from EM patients.
• Bioinformatic analysis, including Bayesian normalization and Benjamini-Hochberg correction, was performed.

Main Results:

• A total of 2,278 miRNAs were sequenced, with 658 analyzed for expression.
• Ten miRNAs were found to be statistically significantly differentially expressed between EM and MM patients (p < 0.0005).
• Specific miRNAs identified include miR-26a-5p, miR-26b-5p, miR-30e-5p, and others.

Conclusions:

• This pilot study demonstrates distinct miRNA expression profiles in MM patients with extramedullary relapse.
• The identified differentially expressed miRNAs may serve as potential biomarkers for EM in multiple myeloma.
• Further validation using qPCR on a larger patient cohort is planned.